Diphtheria tetanus pertussis-hepatitis B vaccine - GlaxoSmithKline

Drug Profile

Diphtheria tetanus pertussis-hepatitis B vaccine - GlaxoSmithKline

Alternative Names: Diphtheria-tetanus-pertussis-hep B vaccine (Tritanrix-HepB) - GlaxoSmithKline; DPT + Hepa B vaccine - GlaxoSmithKline; DTPw-HBV vaccine - GlaxoSmithKline; Tritanrix HB - GlaxoSmithKline; Tritanrix HepB; Tritanrix-HepB

Latest Information Update: 22 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 20 Dec 2013 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts a positive scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004 for Tritanrix® HB for immunisation against diphtheria, tetanus pertussis and hepatitis B in infants from 6 weeks onwards
  • 05 May 2011 Launched for Diphtheria in India (IM)
  • 05 May 2011 Launched for Diphtheria in Vietnam (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top